

**Appendix 1: Updated National Advisory Committee on Immunization recommendations on the human papillomavirus (HPV) immunization schedule<sup>1</sup>**

- **Recommendation 1: Healthy females (9–14 years of age)**

Either a 2-dose or 3-dose schedule (with at least 6 months between the first and last dose) of the nonavalent, quadrivalent or bivalent HPV vaccine is recommended for immunocompetent, non-HIV-infected females 9–14 years of age.

- **Recommendation 2: Healthy females (≥ 15 years of age)**

A 3-dose schedule of the nonavalent, quadrivalent or bivalent HPV vaccine is recommended for females 15 years of age and older.

- **Recommendation 3: Healthy males (9–14 years of age)**

Either a 2-dose or 3-dose schedule (with at least 6 months between the first and last dose) of the nonavalent or quadrivalent HPV vaccine is recommended for immunocompetent, non-HIV-infected males 9–14 years of age.

- **Recommendation 4: Healthy males (≥ 15 years of age)**

A 3-dose schedule of the nonavalent or quadrivalent HPV vaccine is recommended for males 15 years of age and older.

- **Recommendation 5: Immunocompromised individuals and immunocompetent HIV-infected individuals**

A 3-dose schedule of the nonavalent or quadrivalent (for females or males) or bivalent (for females) HPV vaccine is recommended for individuals who are immunocompromised and for immunocompetent HIV-infected individuals. There is insufficient evidence to recommend a 2-dose schedule in these populations.

1. Updated Recommendations on Human Papillomavirus (HPV) Vaccines: 9-valent HPV vaccine 2-dose immunization schedule and the use of HPV vaccines in immunocompromised populations: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization. Ottawa: Public Health Agency of Canada; 2017. Available: <https://www.canada.ca/en/public-health/services/publications/healthy-living/updated-recommendations-human-papillomavirus-immunization-schedule-immunocompromised-populations.html> (accessed 2017 May 30).